Paasa Logo
Nektar Therapeutics logo
NKTRNASDAQMarket closedOpens 9:30am ET

Nektar Therapeutics

$57.06Last updated
-$2.32 (3.91%)Past day
Timezone

Nektar Therapeutics (NASDAQ: NKTR) is trading at $57.06, about ₹5,473 at today's USD/INR rate, as of 25 Sep 2026, 4:00 PM ET, down 3.91% today. Indian residents can buy Nektar Therapeutics from India on Paasa under the RBI's Liberalised Remittance Scheme.

Quote

Open:$59.77
Previous close:$59.38
Volume:2.53M

Today's low

$57.04

Today's high

$60.98

52 week low

$33.40

52 week high

$109.00

NKTR opened at $59.77, closed previously at $59.38, and has traded between $33.40 and $109.00 over the past 52 weeks.

About

Nektar Therapeutics is a biopharmaceutical firm dedicated to the global discovery and advancement of therapies addressing significant unmet medical requirements. Central to its robust pipeline is Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist. This drug is currently in Phase 3 clinical trials for metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, head and neck squamous cell carcinoma, and adjuvant melanoma. It is also being evaluated in Phase 2 for renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; Phase 1/2A for head and neck squamous cell carcinoma; Phase 1/2 for various solid tumors; and Phase 1B for COVID-19. Additionally, Nektar is developing NKTR-358, a cytokine Treg stimulant, which is in Phase 2 trials for systemic lupus erythematosus and ulcerative colitis, and Phase 1B for atopic dermatitis and psoriasis. Their portfolio further includes NKTR-255, an IL-15 receptor agonist, undergoing Phase 1/2 trials for non-Hodgkin's lymphoma, multiple myeloma, head and neck cancer, and colorectal cancer. Another investigational compound, NKTR-262, a toll-like receptor agonist, is in Phase 1/2 trials for solid tumors. The company is also advancing several other drug candidates. Nektar Therapeutics maintains strategic collaboration agreements with a multitude of pharmaceutical entities, including Takeda Pharmaceutical Company Ltd., AstraZeneca AB, UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Bausch Health Companies Inc., Pfizer Inc., Amgen Inc., UCB Pharma (Biogen), Bristol-Myers Squibb Company, Baxalta Incorporated, Eli Lilly and Company, Merck KGaA, and SFJ Pharmaceuticals, Inc. Established in 1990, Nektar Therapeutics is headquartered in San Francisco, California.

Country
US
CEO
Howard W. Robin
Exchange listed on
NASDAQ
Industry
Biotechnology
Base currency
USD
Full Time Employees
63
Sector
Healthcare
IPO date
03/05/1994

Key statistics

Avg. volume

981.38K

Market cap

$1.64B

P/E Ratio

-8.52

Price-to-sales ratio

29.99

Enterprise value

$1.73B

Free cash flow yield

-14.30%

Debt-to-equity ratio

0.15

Return on equity

-37.99%

ROIC

-12.53%

Beta

1.15

Dividend yield

0.00%

Last dividend

$0.00

Financial overview

Revenue

$55.23M

Earnings per share

-$9.73

Free cash flow

-$208.68M

Net profit margin

-287.84%

Gross margin

99.36%

EBITDA

-$137.00M

Revenue growth

-43.89%

Similar securities

This is not an investment recommendation

How to buy Nektar Therapeutics from India

Indian residents can buy Nektar Therapeutics shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.

  1. Open a Paasa account

    Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.

  2. Add funds under LRS

    Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars.

  3. Search for Nektar Therapeutics and place an order

    Find Nektar Therapeutics by name or by its ticker, NKTR, and choose an order type. You can buy by amount or by quantity — fractional shares mean there is no minimum trade size. Nektar Therapeutics trades 7:00 pm – 1:30 am IST; orders can only execute during that window.

  4. Track holdings and download tax reports

    Follow your Nektar Therapeutics position in USD and INR. Nektar Therapeutics pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.

Read the full guide: how to invest in Nektar Therapeutics from India

Trading and taxes when buying Nektar Therapeutics from India

Trading and limits

Trading hours
9:30 am – 4:00 pm ET
LRS limit
$250,000Per financial year, under the RBI's Liberalised Remittance Scheme.

Tax for Indian residents

TCS on remittance
20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
Capital gains in India
12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
Dividends
NoneNektar Therapeutics does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained
US estate tax
May applyUS-situs assets such as US-listed shares can be exposed to US estate tax for non-US persons.US estate tax calculator

Custody. Shares are held in your own name at Interactive Brokers LLC and are SIPC-insured up to $500,000 in total, including $250,000 for cash.

FAQs

Can Indian residents buy Nektar Therapeutics stock?

Yes. Nektar Therapeutics (NKTR) has been listed on NASDAQ since 1994, in the Biotechnology industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars. Shares are held in your own name at Interactive Brokers LLC and are SIPC-insured up to $500,000 in total, including $250,000 for cash.

How much does one Nektar Therapeutics share cost in rupees?

One Nektar Therapeutics share is $57.06 — about ₹5,473 at a USD/INR rate of 95.92 on 25 Sep 2026. Both the Nektar Therapeutics price and the rupee rate move during the day, so the rupee cost changes with them.

What are the LRS and TCS rules for buying Nektar Therapeutics from India?

Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.

Can I buy whole shares of Nektar Therapeutics?

Yes. One Nektar Therapeutics share is $57.06, and you can buy as many whole shares as you like. You can also buy by amount rather than by quantity: there is no minimum trade size, and Paasa supports fractional investing in Nektar Therapeutics.

How are gains on Nektar Therapeutics shares taxed in India?

The US does not levy capital gains tax on shares for Indian residents, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the USD/INR rate on the purchase and the sale date, so the rupee move counts alongside the Nektar Therapeutics price. Paasa issues a capital-gains statement for your return.

Does Nektar Therapeutics pay a dividend?

No. Nektar Therapeutics does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.

When can I trade Nektar Therapeutics from India?

NASDAQ trades 7:00 pm – 1:30 am IST in Indian time, so the close lands after midnight. The window shifts to 8:00 pm – 2:30 am IST when the US is on standard time. Orders can only execute during that window.

Is there estate or inheritance tax on Nektar Therapeutics shares held from India?

US-situs assets such as US-listed shares can be exposed to US estate tax for non-US persons. It applies to your overall holdings in that jurisdiction rather than to any one position. Paasa's US estate tax calculator shows the exposure for a given portfolio value.

Do I have to declare Nektar Therapeutics shares in my Indian tax return?

Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your Nektar Therapeutics holding, its cost and its closing value.

How do I sell Nektar Therapeutics and bring the money back to India?

You sell during market hours (7:00 pm – 1:30 am IST) and the proceeds settle in USD in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.